⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 19, 2024International Journal of Clinical Pharmacology and Therapeutics

Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial

Yanping Liu Lang Lü Man Xu Juanmin Tao Yuping Ning Yan Shi Yanfen Dong Qingqing Cao Jun Ma Yan Qiu

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the bioequivalence of two different afatinib dimaleate formulations in healthy Chinese subjects under fasting conditions and to assess their pharmacokinetic and safety profiles.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e5bc3fb6db64358755481c https://doi.org/10.5414/cp204514

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions2024
2Evaluation of Bioequivalence for Avapritinib Tablets in Chinese Participants Under Fasting Conditions Using a Reference‐Scaled Average Bioequivalence Method2024 · 1 citations
3Pharmacokinetic and Bioequivalence Evaluation of Febuxostat 40 mg Tablets in Healthy Chinese Subjects Under Fasting and Fed ConditionsEarly-Phase Clinical Trial · 2026
4Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions2024 · 1 citations
5The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablet (20 mg) in Chinese Healthy Subjects Under Fasting Conditions2024